Literature DB >> 1667388

DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a potent bradykinin B1 receptor antagonist.

K Wirth1, G Breipohl, J Stechl, J Knolle, S Henke, B Schölkens.   

Abstract

DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]BK is a potent and stable B1 bradykinin (BK) receptor antagonist which was one order of magnitude more potent (IC50 1.2 x 10(-8) M) in the isolated rabbit aorta than the known selective B1 BK receptor antagonist, desArg9-[Leu8]BK (IC50 1.1 x 10(-7) M). DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]BK is the desArg10 derivative of Hoe140, a new, potent, stable, selective and long-acting B2 BK receptor antagonist. In B2 organ preparation it was three orders of magnitude less potent than Hoe140. Since it is potent and stable it could contribute to the investigation of B1 BK receptor function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1667388     DOI: 10.1016/0014-2999(91)90824-a

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes.

Authors:  João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos
Journal:  Br J Pharmacol       Date:  2004-11-01       Impact factor: 8.739

2.  Bradykinin (B2) independent effect of captopril on the development of pressure overload cardiac hypertrophy.

Authors:  M Turcani; H Rupp
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

3.  Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats.

Authors:  F Cloutier; R Couture
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat.

Authors:  Mohamed Abdouh; Ashraf Khanjari; Nadia Abdelazziz; Brice Ongali; Réjean Couture; Haroutioun M Hasséssian
Journal:  Br J Pharmacol       Date:  2003-09       Impact factor: 8.739

5.  LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia.

Authors:  Li Ding-Zhou; Isabelle Margaill; Bruno Palmier; Didier Pruneau; Michel Plotkine; Catherine Marchand-Verrecchia
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

6.  Correlation between brain bradykinin receptor binding sites and cardiovascular function in young and adult spontaneously hypertensive rats.

Authors:  Frank Cloutier; Brice Ongali; Maria M Campos; Gaétan Thibault; Witold Neugebauer; Réjean Couture
Journal:  Br J Pharmacol       Date:  2004-04-05       Impact factor: 8.739

7.  Bradykinin B1 receptors in the rabbit urinary bladder: induction of responses, smooth muscle contraction, and phosphatidylinositol hydrolysis.

Authors:  S K Butt; L G Dawson; J M Hall
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

8.  Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors.

Authors:  M Abdouh; S Talbot; R Couture; H M Hasséssian
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

9.  Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats.

Authors:  Hiroshi Ito; Izumi Hayashi; Tohru Izumi; Masataka Majima
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

10.  Up-regulation of kinin B1 receptor in the lung of streptozotocin-diabetic rat: autoradiographic and functional evidence.

Authors:  Rose Mari J Vianna; Brice Ongali; Domenico Regoli; João Batista Calixto; Réjean Couture
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.